reptides › weight loss › tirzepatide

tirzepatide

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

tier S · weight loss · 20.9% SURMOUNT-1 mean change at 15 mg

verdict

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

if you are comparing Zepbound and Mounjaro: Both contain tirzepatide and use subcutaneous ready-to-use presentations. Zepbound is labeled for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is labeled for type 2 diabetes in adults and patients aged 10 years and older.

if you are comparing it with semaglutide: SURMOUNT-5 was an open-label 72-week comparison of maximum tolerated tirzepatide and semaglutide doses in 751 adults with obesity and no diabetes. Mean weight change was -20.2 percent versus -13.7 percent.

if you are asking about lean tissue: The SURMOUNT-1 DXA substudy reported changes in lean mass, not direct muscle measurements. Lean mass fell 10.9 percent from baseline with tirzepatide.

This is an evidence record, not a dosing recommendation.

what it is

Tirzepatide is one molecule that activates both GIP and GLP-1 receptors. Current US products are Zepbound for labeled weight-management and obstructive-sleep-apnea uses and Mounjaro for type 2 diabetes. Both are ready-to-use subcutaneous products.

key facts

  • molecular weight: ~4813.5 Da
  • amino acids: 39 aa
  • half-life: ~5 days
  • type: dual GIP and GLP-1 receptor agonist

frequently asked questions

What is tirzepatide?

It is a dual GIP and GLP-1 receptor agonist sold in the US as Zepbound and Mounjaro under distinct labels.

Is the adipose mechanism proven in people?

No. The cited white-adipose glucose-disposal result came from obese mice, including GLP-1-receptor-null mice. It is preclinical evidence only.

Did SUMMIT show a mortality benefit?

No mortality benefit was established. The favorable composite was driven by fewer worsening-heart-failure events, while cardiovascular deaths were numerically 8 with tirzepatide and 5 with placebo.

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.

reptides.